Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: A brake fluid pressure control device for vehicles with bar handle which is configured to start a holding control of a fluid pressure of a wheel brake according to wheel deceleration calculated based on a wheel speed of the vehicle is provided. In the brake fluid pressure control device, the vehicle includes an acceleration sensor which is configured to detect acceleration in a front-rear direction of the vehicle, acceleration, detected by the acceleration sensor, which occurs in a rearward direction when the vehicle is decelerating is detected as a positive value, and the holding control is started when it is judged that the acceleration detected by the acceleration sensor is larger than or equal to a detection acceleration threshold value and the wheel deceleration is smaller than or equal to a wheel deceleration threshold value.

Abstract: A brake fluid pressure control device for vehicles with bar handle which is configured to start a holding control of a fluid pressure of a wheel brake according to wheel deceleration calculated based on a wheel speed of the vehicle is provided. In the brake fluid pressure control device, the vehicle includes an acceleration sensor which is configured to detect acceleration in a front-rear direction of the vehicle, acceleration, detected by the acceleration sensor, which occurs in a rearward direction when the vehicle is decelerating is detected as a positive value, and the holding control is started when it is judged that the acceleration detected by the acceleration sensor is larger than or equal to a detection acceleration threshold value and the wheel deceleration is smaller than or equal to a wheel deceleration threshold value.

Abstract: A brake fluid pressure control device for vehicles with bar handle, includes: an acceleration acquiring unit which is configured to acquire acceleration that occurs in the vehicle; and a control unit which is configured to judge a probability of occurrence of a rear-wheel lift based on the acceleration acquired by the acceleration acquiring unit, and which is configured to perform a pressure reduction control on a front wheel brake when judging that the occurrence of the rear-wheel lift is probable, the control unit which is configured to adjust a degree of pressure reduction of the pressure reduction control based on a differentiation value of the acceleration acquired by the acceleration acquiring unit.

Abstract: A brake control device for vehicles with bar handle includes: a wheel speed obtaining unit obtaining a speed of a wheel; an estimated vehicle body speed setting unit setting an estimated vehicle body speed; a control unit performing fluid pressure control to raise, reduce or hold a brake fluid pressure; and a bank angle obtaining unit obtaining a bank angle. The estimated vehicle body setting unit sets a limit value of a change amount when the estimated vehicle body speed decreases at a time of braking of the vehicle, and sets the estimated vehicle body speed based on the limit value when a deceleration amount of the speed of the wheel on a braked side is larger than the limit value, and the estimated vehicle body speed setting unit corrects the limit value so that the change amount decreases as the obtained bank angle increases.

Abstract: The present disclosure provides a rutile-type niobium oxynitride having a rutile-type crystal structure and represented by the chemical formula NbON. The present disclosure also provides a semiconductor structure (100) including: a substrate (110) having at least one principal surface composed of a rutile-type compound having a rutile-type crystal structure; and a niobium oxynitride (for example, a rutile-type niobium oxynitride film (120)) grown on the one principal surface of the substrate (110), the niobium oxynitride having a rutile-type crystal structure and being represented by the chemical formula NbON.

Abstract: The present disclosure provides an anatase-type niobium oxynitride having an anatase-type crystal structure and represented by the chemical formula NbON. The present disclosure also provides a semiconductor structure (100) including: a substrate (110) having at least one principal surface composed of a perovskite-type compound having a perovskite-type crystal structure; and a niobium oxynitride (for example, an anatase-type niobium oxynitride film (120)) grown on the one principal surface of the substrate (110), the niobium oxynitride having an anatase-type crystal structure and being represented by the chemical formula NbON.

Abstract: Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted ?-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted ?-cyclodextrin.

Abstract: Provided are: a potassium ion secondary battery which is not susceptible to deterioration of charge/discharge capacity even if charging and discharging are repeated, and which has a long service life as a secondary battery; a potassium ion capacitor; a negative electrode for the potassium ion secondary battery; and a negative electrode for the potassium ion capacitor. A negative electrode for potassium ion secondary batteries and a negative electrode for potassium ion capacitors, each of which contains a carbon material that is capable of absorbing and desorbing potassium and a binder that contains a polycarboxylic acid and/or a salt thereof. A potassium ion secondary battery which is provided with the negative electrode or the capacitor. A binder for negative electrodes of potassium ion secondary batteries or negative electrodes of potassium ion capacitors, which contains a polycarboxylic acid and/or a salt thereof.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted ?-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted ?-cyclodextrin.

Abstract: To provide an ethylene/tetrafluoroethylene copolymer sheet excellent in the mechanical strength and the outer appearance, continuously produced by extrusion, and a process for producing it. An ethylene/tetrafluoroethylene copolymer sheet obtained by extrusion, which is characterized by having R0/d (wherein R0 is an in-plane phase difference [unit: nm], and d is a thickness [unit: nm]) of at most 3.0×10?3, and a thickness of more than 300 ?m, and a process for producing it.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: A vehicle rear wheel lift tendency judgment device: includes a first deceleration obtaining device for obtaining a first deceleration along a first straight line, being a component in a first direction of an acceleration on a center of gravity, and a second deceleration obtaining device for obtaining a second deceleration along a second straight line, being a component in a second direction of the acceleration; judges that a rear wheel tends to be lifted, when the first deceleration is greater in the first direction than a first threshold, or when the second deceleration is greater in the second direction than a second threshold; and performs at least one of setting for shifting the first threshold in a direction opposite to the first direction and setting for shifting the second threshold in a direction opposite to the second direction, when a second-deceleration change rate being a change amount in the second deceleration per unit time becomes greater in the second direction than a change-rate threshold, en

Abstract: Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted ?-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted ?-cyclodextrin.

Abstract: A wireless communication apparatus is adapted to provide a wireless area, and includes an inferencer and a controller. The inferencer is adapted to infer a type of a terminal device that is requesting a new connection, based on information obtained through a previous connection in the wireless area. The controller is adapted to control a communication with the terminal device based on the inferred type.

Abstract: An engine includes a crank chamber in which pressure fluctuation occurs and a carburetor including a diaphragm fuel pump. The diaphragm fuel pump includes a pump chamber configured to suck in and eject fuel and a diaphragm chamber to which a pressure that drives the pump chamber is supplied. The diaphragm chamber and the crank chamber communicate with one another in a state in which a negative pressure is created in the crank chamber.

Abstract: A base station that forms a second cell that overlaps with a first cell formed by a different base station includes a determining unit that determines a state of implementation of inter-cell interference coordination that is performed between the first cell and the second cell by the different base station, and a control unit that estimates an offset value set by the different base station for a downlink reception power value of the second cell, based on first reception power of the second cell in a user terminal at the time of non-implementation of the inter-cell interference coordination and based on second reception power of the second cell in the user terminal at the time of implementation of the inter-cell interference coordination, and adjusts the downlink reception power value in the user terminal based on the estimated offset value.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.